Filing Analysis
MAIA Biotechnology, Inc. announced the voting results from its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders re-elected two Class I directors and ratified the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
🚩 Red Flags
- There was significant shareholder dissent/withholding for director nominee Louie Ngar Yee, who received 8,796,832 'Withheld' votes compared to 16,658,677 'For' votes (approximately 34.6% withheld of votes cast).
📋 Key Facts
- The Annual Meeting was held on May 21, 2026, with 37,547,754 shares represented, constituting a 61.88% quorum of the 60,671,491 shares outstanding as of the March 23, 2026 record date.
- Class I directors Louie Ngar Yee and Steven Chaouki were re-elected to three-year terms expiring in 2029.
- The appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 37,278,294 votes in favor.
MAIA Biotechnology has terminated its At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC, effective seven business days after May 14, 2026. The company had recently raised approximately $5.68 million through the sale of 3.1 million shares under this facility.
📋 Key Facts
- Termination of the sales agreement dated February 14, 2024, with H.C. Wainwright & Co., LLC.
- Suspension of sales was effective as of May 14, 2026.
- Since the March 28, 2025 prospectus supplement, the company sold 3,116,012 shares for gross proceeds of $5,680,924.
- The March 2025 prospectus supplement had a total capacity of $11,200,000, meaning the company terminated the agreement with roughly half the capacity remaining.
MAIA Biotechnology announced the activation of its first U.S. clinical trial site for an ongoing international Phase 2 expansion trial. The study is evaluating a novel telomere-targeting treatment for patients with advanced non-small cell lung cancer (NSCLC).
📋 Key Facts
- Activated the first U.S. clinical trial site on April 16, 2026
- The trial is an ongoing international Phase 2 expansion study
- The treatment is a novel telomere-targeting therapy for advanced Non-Small Cell Lung Cancer (NSCLC)
- The announcement was made via a press release incorporated into the 8-K filing
MAIA Biotechnology announced that a recent $33 million capital raise is expected to fully fund its ongoing pivotal Phase 3 clinical trial of ateganosine, a novel telomere-targeting anticancer therapy. This capital infusion is intended to cover the costs of the trial through completion, addressing a major funding milestone for the company.
📋 Key Facts
- The company raised $33 million in a recent capital offering.
- Management expects these funds to fully fund the ongoing pivotal Phase 3 trial of ateganosine.
- Ateganosine is described as a novel telomere-targeting anticancer therapy.
- The filing was made under Item 8.01 (Other Events) on April 8, 2026.
MAIA Biotechnology approved one-time cash bonuses for its CEO and Head of Finance totaling $362,610. The bonuses were awarded specifically for their efforts regarding a recent capital raise.
🚩 Red Flags
- Cash bonuses awarded specifically for capital raising activities can be viewed as misaligned incentives, as management is being rewarded for dilutive events.
- Significant cash outflow for executive bonuses in a micro-cap biotech company which typically requires high cash reserves for R&D.
📋 Key Facts
- CEO Vlad Vitoc was awarded a one-time bonus of $312,610.
- Head of Finance Jeffrey Himmelreich was awarded a one-time bonus of $50,000.
- The bonuses were approved by the Board on March 27, 2026, and paid on March 31, 2026.
- The payments were made in consideration for efforts related to the company's recent capital raise.
MAIA Biotechnology announced positive clinical data from its ongoing Phase 2 trial for Non-Small Cell Lung Cancer (NSCLC). The company reported that eight patients in the study have achieved overall survival exceeding two years.
📋 Key Facts
- The report was filed on March 31, 2026, under Item 8.01 (Other Events).
- The clinical trial is an ongoing Phase 2 study targeting Non-Small Cell Lung Cancer (NSCLC).
- Eight patients in the trial have reached an overall survival milestone of more than 24 months.
- The data was released via a press release titled 'MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer'.
MAIA Biotechnology presented clinical data from its THIO-101 trial at the European Lung Cancer Congress (ELCC) 2026. The data highlights sustained therapeutic benefits in relapsed non-small cell lung cancer (NSCLC) patients treated with Ateganosine and Immune Checkpoint Inhibitors.
📋 Key Facts
- Presented a poster titled 'Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation' at the ELCC in Copenhagen on March 27, 2026.
- The clinical data is derived from the THIO-101 trial.
- The study focuses on relapsed NSCLC patients treated with Ateganosine (THIO) in combination with Immune Checkpoint Inhibitors (ICI).
- The poster was filed as Exhibit 99.1 and made available on the company's website.
MAIA Biotechnology entered into an underwriting agreement for a $30 million public offering of 20 million shares of common stock at $1.50 per share. The offering closed on March 4, 2026, with proceeds earmarked for clinical trials and general working capital.
🚩 Red Flags
- Potential for significant shareholder dilution given the 20,000,000 share count relative to micro-cap status.
- The 60-day lock-up period is relatively short for a public offering.
📋 Key Facts
- Offering of 20,000,000 shares of common stock at a public price of $1.50 per share.
- Gross proceeds of approximately $30.0 million before expenses.
- Underwriter Konik Capital Partners, LLC purchased shares at $1.425 per share (5% discount).
- Underwriter granted a 30-day option to purchase up to 3,000,000 additional shares to cover over-allotments.
- Company officers and directors entered into 60-day lock-up agreements.
- The offering closed on March 4, 2026.
MAIA Biotechnology issued a 2026 Letter to Shareholders and a press release providing updates on its clinical development pipeline. The communications highlight Phase 3 momentum and the company's potential within the $50 billion immunotherapy market.
📋 Key Facts
- Issued 2026 Letter to Shareholders on February 24, 2026
- Released press release titled 'MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market'
- Disclosed progress in the development pipeline and Phase 3 clinical momentum
- The filing includes the full text of the shareholder letter and press release as exhibits
MAIA Biotechnology issued a press release regarding the advancement of its Ateganosine cancer treatment program and provided an outline for 2026 clinical milestones.
📋 Key Facts
- Company announced progress in its Ateganosine cancer treatment program.
- The company outlined specific clinical milestones targeted for the year 2026.
- Filing includes a press release (Exhibit 99.1) detailing growth momentum and R&D updates.
MAIA Biotechnology, Inc. filed an 8-K to provide presentation materials intended for use at the Biotech Showcase in San Francisco on January 13, 2026.
📋 Key Facts
- The company released presentation materials via Item 7.01 (Regulation FD Disclosure).
- Materials were presented at the Biotech Showcase in San Francisco on January 13, 2026.
- Presentation materials are also made available on the company's website.
MAIA Biotechnology entered into a Securities Purchase Agreement on December 16, 2025, to conduct a private placement of common stock and warrants totaling approximately $2.25 million. The funds are intended to finance Phase II clinical trial costs (THIO-101) and general working capital.
🚩 Red Flags
- Related-party transactions: Significant portion of the offering involves directors purchasing shares/warrants ($219,998).
- Dilution risk: Issuance of over 1 million new shares plus warrants for an equal amount of shares.
- Warrant overhang: Warrants are exercisable in six months at $1.36, which may create future dilution.
📋 Key Facts
- Total expected gross proceeds: ~$2,253,896.
- Issuance of 1,053,751 Investor Shares at $1.224 per share plus warrants to purchase an equal number of shares.
- Warrants are exercisable at $1.36 (Minimum Price) starting six months after issuance for a term of three years.
- Directors participated in the placement: 179,737 Director Shares and corresponding warrants were issued to board members.
- Specific director participation: Louie Ngar Yee ($100k), Stan Smith ($70k), and Steven Chaouki ($50k).
- Use of proceeds: Funding for Step 1 of Part C of the Phase II THIO-101 trial and working capital.
- Expected closing date: December 18, 2025.
MAIA Biotechnology issued multiple press releases on December 11, 2025, announcing the initiation of a Phase 3 pivotal trial for Ateganosine (THIO-104) and reporting continued insider buying.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- First patient has been dosed in the THIO-104 Phase 3 Pivotal Trial evaluating Ateganosine as a third-line treatment for Advanced Non-Small Cell Lung Cancer (NSCLC).
- The company reported ongoing insider buying activity throughout 2025.
- Ateganosine is being developed for advanced NSCLC indications.
MAIA Biotechnology, Inc. issued a press release regarding its strategic focus on the $50B immunotherapy market through its telomere-targeting approach.
📋 Key Facts
- Company released a press statement titled 'MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach'.
- The filing is an 8-K under Item 8.01 (Other Events).
- Report date: December 10, 2025.
MAIA Biotechnology issued an 8-K to announce a press release regarding clinical program momentum for Ateganosine at the SITC 2025 conference.
📋 Key Facts
- The filing is an announcement of a press release dated November 21, 2025.
- The press release focuses on the 'Ateganosine Clinical Program' momentum.
- The update was presented in conjunction with SITC 2025 (Society for Immunotherapy of Cancer).
MAIA Biotechnology, Inc. issued an 8-K to announce a press release regarding the CEO's presentation on telomere targeting efficacy at the 2025 Smart Diaspora Conference in Romania.
📋 Key Facts
- The filing is related to a press release titled 'MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation.'
- Date of report: November 20, 2025.
- The company is an emerging growth company.
MAIA Biotechnology, Inc. announced the presentation of two clinical trial posters at the Society for Immunotherapy of Cancer (SITC 2025) conference regarding its Ateganosine (THIO) studies.
📋 Key Facts
- Presentation of THIO-104 Poster: Phase 3 study of Ateganosine sequenced with ICI vs Standard of Care in ICI-Resistant Advanced NSCLC, presented on November 7, 2025.
- Presentation of THIO-101 Poster: Phase 2 study of Ateganosine in combination with ICI in patients with advanced NSCLC resistant to prior ICI and chemotherapy, scheduled for presentation on November 10, 2025.
- Both posters are being made available via the company's website.
MAIA Biotechnology announced the presentation of a trial-in-progress poster at the 2025 AACR-NCI-EORTC International Conference and reported enrollment of five patients in its THIO-101 Phase 2 expansion phase.
📋 Key Facts
- Company presented a 'trial in progress' poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- Enrolled five patients from Taiwan and Turkey into the THIO-101 Phase 2 expansion phase trial.
MAIA Biotechnology, Inc. presented a scientific poster regarding the results of its Phase 2 THIO-101 clinical trial at the AACR-NCI-EORTC International Conference on October 24, 2025.
📋 Key Facts
- Presented data for 'Phase 2 Study of Ateganosine (THIO) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)'.
- The trial focuses on patients resistant to prior ICI and chemotherapy.
- Presentation occurred at the AACR-NCI-EORTC International Conference in Boston, MA.
- Data was made available via a poster posted to the Company's website on October 24, 2025.
MAIA Biotechnology issued an 8-K to furnish a press release regarding clinical trial data and to include posters presented at the ESMO Congress 2025. The filing focuses on Phase 2 and Phase 3 clinical trial updates for Ateganosine (THIO) in Non-Small Cell Lung Cancer (NSCLC).
📋 Key Facts
- Issued press release regarding 30-month patient survival data from an ongoing Phase 2 clinical trial in NSCLC.
- Presented 'THIO-101 Trial Poster' at the ESMO Congress 2025 (Berlin, Germany) starting October 19, 2025.
- Presented 'THIO-104 Trial Poster' regarding a Phase 3 study of Ateganosine sequenced with ICI versus Standard of Care Chemotherapy.
- The clinical data pertains to patients with advanced NSCLC resistant to prior ICI and chemotherapy.
MAIA Biotechnology entered into a Securities Purchase Agreement to conduct a private placement of common stock and warrants for approximately $736,600. The proceeds are earmarked for Phase II clinical trial costs (THIO-101) and general working capital.
🚩 Red Flags
- Small capital raise ($736k) suggests limited runway or high burn rate typical of micro-cap biotech.
- Issuance of warrants at a premium to the current share price ($1.52 vs $1.22), which may lead to future dilution.
📋 Key Facts
- Total aggregate purchase price: approximately $736,600.
- Issuance of 603,769 shares of common stock at $1.22 per share.
- Issuance of warrants to purchase up to 603,769 shares at an exercise price of $1.52.
- Warrants are exercisable in six months and have a three-year term.
- Securities are being issued as restricted securities under Rule 144 without registration rights.
- Expected closing date: October 15, 2025.
MAIA Biotechnology, Inc. announced the launch of a new digital asset treasury strategy focused on top-tier cryptocurrency assets via a press release issued on October 7, 2025.
🚩 Red Flags
- Strategic pivot/diversification into highly volatile cryptocurrency assets by a biotechnology company may indicate unconventional treasury management or potential liquidity concerns, though not explicitly stated.
📋 Key Facts
- Company is launching a digital asset treasury strategy.
- The strategy focuses specifically on 'top-tier cryptocurrency assets'.
- Announcement made via press release under Item 8.01.
MAIA Biotechnology entered into a Securities Purchase Agreement to raise approximately $2.25 million through the private placement of common stock and warrants at $1.30 per share. The company also amended existing warrants from February 2025 to lower their exercise price from $1.87 to $1.30.
🚩 Red Flags
- Significant dilution: Issuance of over 1.7 million new shares plus warrants, alongside a reduction in exercise price for existing warrants.
- Warrant Downround/Refixing: The amendment to reduce the exercise price of previously issued warrants from $1.87 to $1.30 is a strong signal of downward pressure on share value and dilution for existing holders.
- Related-party transaction: A director (Stan Smith) participated in the private placement.
- Reliance on high-cost financing: The company is raising capital specifically to fund clinical trial costs, indicating a need for immediate liquidity.
📋 Key Facts
- Private placement of 1,714,536 shares of common stock and an equal number of warrants at $1.30 per share.
- FGMK Business Holdings, LLC (a >5% holder) subscribed for 769,230 shares and warrants for ~$1 million.
- Director Stan Smith participated in the placement, purchasing 19,230 shares and warrants at $1.30 per share.
- Warrants are exercisable at $1.57 starting six months after issuance with a three-year term.
- The company amended existing warrants (issued Feb 24, 2025) to reduce the exercise price from $1.87 to $1.30 for 1,396,667 shares.
- Net proceeds are intended to fund Step 1 of Part C of the Phase II trial THIO-101 and working capital.
MAIA Biotechnology, Inc. announced that it has been awarded a $2.3 million grant from the National Institutes of Health (NIH). The funds are designated to expand the THIO-101 Phase 2 clinical trial for ateganosine in treating advanced non-small cell lung cancer.
📋 Key Facts
- Awarded a $2.3 million grant by the National Institutes of Health (NIH) on September 24, 2025.
- Grant purpose: Expansion of the THIO-101 Phase 2 clinical trial.
- Target indication: Third-line treatment for patients with advanced non-small cell lung cancer.
- Drug candidate: Ateganosine.
MAIA Biotechnology entered into inducement agreements to allow existing warrant holders to exercise their warrants at a significantly reduced price of $1.30 per share. This action will result in the issuance of 440,503 shares of common stock and is expected to generate approximately $572,654 in gross proceeds.
🚩 Red Flags
- Significant dilution: The company is issuing over 440k shares at a heavily discounted rate to existing holders.
- Related-party transaction: David Smith, son of Company director Stan Smith, is participating in the inducement by exercising 40,000 warrants.
- Large shareholder participation: FGMK Business Holdings, LLC (a >5% holder) is exercising 243,470 warrants.
- Desperation signal: Drastic reduction of exercise prices often indicates a need for immediate cash or an attempt to prevent warrant expiration/litigation.
📋 Key Facts
- Inducement letters signed on September 18, 2025, with a closing date expected around September 22, 2025.
- Warrant exercise price reduced from various levels ($6.00, $2.08, and $2.51) to a flat $1.30 per share.
- Total shares to be issued: 440,503 common shares.
- Expected gross proceeds: approximately $572,654.
- The issuance will be conducted under exemptions from registration (Section 4(a)(2), Rule 506 and/or 3(a)(9)).
- Shares issued will be 'restricted securities' with a restrictive legend.
MAIA Biotechnology, Inc. filed an 8-K to announce the posting of an updated business presentation on its company website.
📋 Key Facts
- The Company posted an updated business presentation on September 12, 2025.
- The presentation is intended to provide summary information regarding the Company's business operations.
- The filing includes a disclaimer that the presentation contains forward-looking statements and should be viewed in context with official SEC filings.
MAIA Biotechnology, Inc. announced positive efficacy data from its THIO-101 Phase 2 Clinical Trial for the treatment of Non-Small Cell Lung Cancer (NSCLC). The filing serves as a formal announcement of clinical progress via an attached press release.
📋 Key Facts
- Announced positive efficacy data from THIO-101 Phase 2 Clinical Trial.
- The trial focused on Non-Small Cell Lung Cancer (NSCLC) indications.
- Data was released/reported on September 11, 2025.
MAIA Biotechnology released efficacy data from its Phase 2 THIO-101 clinical trial via a poster presentation at the 2025 IASLC World Conference on Lung Cancer. The study evaluated THIO sequenced with cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC).
📋 Key Facts
- Clinical Trial: Phase 2 THIO-101 trial.
- Mechanism/Combination: THIO sequenced with immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®).
- Patient Population: Advanced non-small cell lung cancer (NSCLC) patients who failed 2 or more standard-of-care therapy regimens.
- Primary Outcome Mentioned: Improvement in Progression-Free Survival (PFS).
- Event Date: Presented at the 2025 IASLC World Conference on Lung Cancer (WCLC) on September 7, 2025.
MAIA Biotechnology, Inc. announced that the European Patent Office has granted a patent covering ateganosine-based analogues for telomere-targeting anticancer therapy and methods of use in combination with checkpoint inhibitors.
📋 Key Facts
- European Patent Office granted patent for ateganosine-based analogues.
- Patent covers telomere-targeting anticancer therapy applications.
- Covers methods of using ateganosine (THIO) alone or prior to administration of checkpoint inhibitors (CPIs).
- Announcement date: August 13, 2025.
MAIA Biotechnology announced that the FDA has granted Fast Track designation to its drug candidate, Ateganosine, for the treatment of non-small cell lung cancer (NSCLC). The announcement was made via a press release on July 28, 2025.
📋 Key Facts
- FDA granted Fast Track designation for Ateganosine.
- Target indication: Non-small cell lung cancer (NSCLC).
- Announcement date: July 28, 2025.
MAIA Biotechnology, Inc. issued an 8-K to announce the peer-reviewed publication of data validating their second-generation Ateganosine prodrugs for anticancer therapy.
📋 Key Facts
- The filing is a press release announcement regarding scientific validation of product candidates.
- Data pertains to 'Second Generation Ateganosine Prodrugs' intended for anticancer therapy.
- The publication has undergone peer review, which typically increases the credibility of clinical/preclinical data.
MAIA Biotechnology announced the dosing of the first patient in the expansion phase of its Phase 2 clinical trial for Ateganosine, targeting advanced non-small cell lung cancer (NSCLC). This represents a key operational milestone in the company's clinical development pipeline.
📋 Key Facts
- First patient dosed in the expansion portion of the Phase 2 Trial for Ateganosine.
- Target indication: Advanced non-small cell lung cancer (NSCLC).
- Announcement date: July 9, 2025.
MAIA Biotechnology entered into a Stock Purchase Agreement (SPA) with Prevail Partners, LLC to issue up to $587,905 in common stock via an upfront payment and 36 subsequent tranches. The proceeds are earmarked for funding Phase 3 clinical study technologies and services.
🚩 Red Flags
- Related-party transaction potential: The proceeds are being used to pay an affiliate (Prevail Infoworks) of the entity purchasing the stock (Prevail Partners, LLC).
- Dilutive structure: The 36-tranche payment schedule creates ongoing dilution over a long period.
📋 Key Facts
- Total offering amount: $587,905 in common stock.
- Structure: One upfront payment of $58,800.33 followed by 36 equal monthly/periodic tranches of $14,697.33 each.
- Pricing mechanism: 120% of the 30-day VWAP, subject to a Minimum Share Price floor of $1.74.
- Issuance limit: Includes a 19.99% blocker to prevent issuance exceeding 19.99% of outstanding shares.
- Use of proceeds: To pay Prevail Infoworks (an affiliate of the purchaser) for technologies and services related to a Phase 3 study evaluating THIO sequenced with cemiplimab vs. chemotherapy in non-small cell lung cancer.
MAIA Biotechnology, Inc. issued an 8-K to announce the appointment of new members to its Scientific Advisory Board via a press release.
📋 Key Facts
- The company announced the appointment of additional members to its scientific advisory board on June 24, 2025.
- The announcement was made through a press release (Exhibit 99.1).
- The filing is categorized under Item 8.01 (Other Events).
MAIA Biotechnology, Inc. announced a Master Clinical Supply Agreement with Roche via a press release on June 18, 2025.
📋 Key Facts
- The company entered into a Master Clinical Supply Agreement with Roche.
- The announcement was made via a press release dated June 18, 2025.
- MAIA Biotechnology is an emerging growth company listed on the NYSE American.
MAIA Biotechnology entered into inducement agreements to allow existing warrant holders to exercise their warrants at a significantly reduced price of $1.50 per share. This transaction is expected to result in the issuance of 219,283 shares and generate approximately $328,925 in gross proceeds for general corporate purposes.
🚩 Red Flags
- Significant dilution: The company is allowing holders to exercise warrants at a steep discount ($1.50 vs original prices as high as $6.00).
- Low cash infusion: The total gross proceeds (~$329k) are very low relative to typical micro-cap operations, suggesting potential liquidity constraints.
- Warrant overhang/Dilution mechanism: This is a structured attempt to convert warrants into equity, likely to clean up the cap table or provide minor liquidity.
📋 Key Facts
- Inducement letters signed on June 17, 2025, with multiple groups of accredited investors (Pre-IPO, March 2024, November 2024, and December 2024 holders).
- Warrant exercise prices were reduced from a range of $2.08–$6.00 down to a flat $1.50 per share.
- Total shares to be issued: 219,283 common shares.
- Expected gross proceeds: approximately $328,925.
- The transaction is expected to close on or about June 18, 2025.
- Shares will be issued as 'restricted securities' under Section 4(a)(2), Rule 506 and/or 3(a)(9) of the Securities Act.
MAIA Biotechnology issued an 8-K to announce positive clinical efficacy updates and a new responder in its Phase 2 THIO-101 clinical trial for Non-Small Cell Lung Cancer (NSCLC). The filing consists of two press releases detailing advancements in their lead drug candidate's development.
📋 Key Facts
- Date of report: June 5, 2025
- The company issued a positive efficacy update for the Phase 2 THIO-101 clinical trial in Non-Small Cell Lung Cancer (NSCLC).
- A new responder was identified in the NSCLC Phase 2 clinical trial.
- The filing includes two press releases as exhibits (99.1 and 99.2).
MAIA Biotechnology, Inc. released clinical efficacy data from its Phase 2 THIO-101 trial via a poster presented at the 2025 ASCO Annual Meeting. The filing also includes a general business presentation posted to the company's website.
📋 Key Facts
- Phase 2 THIO-101 clinical trial evaluated efficacy of THIO sequenced with cemiplimab (Libtayo®).
- Study population: Patients with advanced non-small cell lung cancer (NSCLC) who failed 2 or more standard-of-care regimens.
- Data was presented as an abstract at the 2025 ASCO Annual Meeting on May 31, 2025.
- The company released a business presentation alongside the clinical poster.
MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement to conduct a private placement of common stock and warrants totaling approximately $695,000. The proceeds are intended to fund Phase II clinical trial costs for THIO-101 and general working capital.
🚩 Red Flags
- Small offering size ($695k) suggests limited runway for a biotech company.
- Related-party transaction: A director (Stan Smith) participated in the private placement to 'align interests'.
📋 Key Facts
- Private placement of 429,999 Investor Shares at $1.50 per share plus warrants to purchase up to 429,999 shares.
- Director Stan Smith participated in the offering, purchasing 33,333 Director Shares and 33,333 Warrants for $50,000.
- Warrant exercise price is $1.71 per share (greater of book or market value).
- Total expected gross proceeds: approximately $695,000.
- Use of proceeds: Step 1 of Part C of the Phase II trial THIO-101 and working capital.
- Closing date expected on May 29, 2025.
MAIA Biotechnology, Inc. announced that stockholders approved an amendment to increase the authorized common stock from 70 million to 150 million shares on May 22, 2025.
🚩 Red Flags
- Significant increase in authorized share count (more than double) often precedes a dilutive equity offering to raise capital.
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation on May 22, 2025.
- Authorized common stock increased from 70,000,000 shares to 150,000,000 shares.
- The change was filed with the Delaware Secretary of State.
MAIA Biotechnology, Inc. held its 2025 Annual Meeting of stockholders on May 22, 2025. The meeting resulted in the re-election of two directors, ratification of Grant Thornton LLP as auditors, and approval to increase authorized common stock from 70 million to 150 million shares.
🚩 Red Flags
- Significant increase in authorized share count (from 70M to 150M) which can lead to future dilution if used for equity financing.
📋 Key Facts
- Annual Meeting held on May 22, 2025, with a quorum present representing ~66.9% of outstanding shares (19,822,242 shares).
- Jean-Manassé Theagène and Stan V. Smith were re-elected to the Board of Directors.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Stockholders approved an amendment to increase authorized common stock from 70,000,000 to 150,000,000 shares.
MAIA Biotechnology entered into a Securities Purchase Agreement on April 14, 2025, to conduct a private placement of common stock and warrants totaling approximately $1.08 million. The proceeds are intended to fund Phase II clinical trial costs (THIO-101) and working capital.
🚩 Red Flags
- Related-party transactions: Directors Stan Smith and Ramiro Guerrero participated in the private placement.
- Dilutive potential: Issuance of warrants covering 50% of the shares sold (633,333 warrants for 633,333 shares).
- Small offering size: $1.08 million is a relatively small amount of capital for a biotech company in clinical trials.
📋 Key Facts
- Aggregate gross proceeds from the offering: approximately $1.08 million.
- Issuance of 633,333 Investor Shares at $1.50 per share plus warrants to purchase up to 633,333 shares.
- Warrants exercise price: $2.05 per share (greater of book or market value).
- Director participation includes 86,667 shares and warrants for a total of $130,000.
- Specific director subscriptions: Stan Smith ($100,000) and Ramiro Guerrero ($30,000).
- Warrants have a one-year exercise commencement period and a six-year term.
- Use of proceeds: Funding for Part C of the Phase II trial THIO-101 and working capital.
MAIA Biotechnology, Inc. released a business presentation on its website to provide summary information regarding the company's operations and business model.
📋 Key Facts
- The company made available a business presentation via its website on April 22, 2025.
- The presentation is filed as Exhibit 99.1.
- The filing contains forward-looking statements regarding the company's future performance and circumstances.
MAIA Biotechnology, Inc. issued a 2025 Letter to Shareholders and a corresponding press release detailing anticipated clinical milestones for its cancer treatment candidates.
📋 Key Facts
- The filing is an announcement of the company's 2025 Letter to Shareholders (Exhibit 99.1).
- The letter details anticipated clinical milestones for various cancer treatment candidates.
- A press release was issued simultaneously on April 1, 2025 (Exhibit 99.2).
MAIA Biotechnology, Inc. released efficacy data from its Phase 2 THIO-101 clinical trial via a poster presentation at the European Lung Cancer Congress 2025. The data evaluates THIO sequenced with cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC).
🚩 Red Flags
- The filing contains significant forward-looking statement disclaimers regarding clinical trial progress, regulatory approvals, and market acceptance.
📋 Key Facts
- Clinical Trial: Phase 2 THIO-101 study.
- Combination Therapy: THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®).
- Patient Population: Advanced non-small cell lung cancer (NSCLC) patients who failed 2 or more standard-of-care therapy regimens.
- Event Date: Presented at the European Lung Cancer Congress on March 28, 2025.
- Disclosure Method: Data presented via a poster/abstract and made available on the company website.
MAIA Biotechnology, Inc. has significantly reduced the maximum aggregate offering price under its existing At The Market (ATM) Sales Agreement with H.C. Wainwright & Co. LLC.
🚩 Red Flags
- Significant reduction (over 60%) in the available ATM offering capacity suggests a potential shift in capital needs or an attempt to manage dilution/market impact.
- The company has already utilized more than half of its original $30M capacity, indicating ongoing reliance on equity financing to fund operations.
📋 Key Facts
- Maximum aggregate offering price decreased from $30,000,000 to $11,200,000.
- The reduction was formalized via a prospectus supplement dated March 26, 2025.
- Company has already sold approximately $6,289,062 in shares under the agreement in the last 12 months.
- Aggregate sales under the Sales Agreement to date total $11,633,086.
MAIA Biotechnology, Inc. filed an 8-K to announce the availability of a business presentation on its website. The filing serves as a vehicle to incorporate these presentation materials by reference.
📋 Key Facts
- Company released a business presentation on March 21, 2025.
- The presentation was posted to the Company's website.
- Exhibit 99.1 contains the presentation materials.
MAIA Biotechnology, Inc. announced that the USAN Council has approved 'Ateganosine' as the nonproprietary name for its anticancer agent THIO.
📋 Key Facts
- USAN Council approval received for the nonproprietary name 'Ateganosine'.
- The name applies to the Company's anticancer agent, THIO.
- Announcement date: March 19, 2025.
MAIA Biotechnology, Inc. announced the initiation of a Phase 3 clinical trial for its THIO Sequenced product in combination with Checkpoint Inhibitors via a press release on February 27, 2025.
📋 Key Facts
- Company issued a press release regarding a Phase 3 Trial of THIO Sequenced with Checkpoint Inhibitor.
- The announcement was made on February 27, 2025.
- The filing includes forward-looking statements regarding clinical study progress and regulatory approvals.
MAIA Biotechnology entered into a Securities Purchase Agreement to conduct a private placement of common stock and warrants totaling approximately $1.43 million. The proceeds are intended to fund Phase 2 clinical trial costs for THIO-101 and general working capital.
🚩 Red Flags
- Small offering size ($1.43M) suggests limited runway for a biotech company in clinical trials.
- Warrants issued at $1.85 (higher than the $1.50 subscription price) indicate potential future dilution.
- Securities are being issued as restricted securities without immediate registration rights.
📋 Key Facts
- Private placement of 894,300 Investor Shares at $1.50 per share.
- Issuance of warrants to purchase up to 894,300 shares at an exercise price of $1.85.
- Total expected gross proceeds: approximately $1.43 million.
- Directors Stan Smith and Ramiro Guerrero participated in the offering via Director Shares/Warrants.
- Proceeds earmarked for Part C of the Phase 2 THIO-101 clinical trial and working capital.
- Expected closing date: February 26, 2025.
MAIA Biotechnology entered into a Securities Purchase Agreement for a private placement of common stock and warrants totaling approximately $2.715 million in gross proceeds. The funds are intended to finance Phase II clinical trial costs (THIO-101) and general working capital.
🚩 Red Flags
- The securities being issued are restricted and do not include registration rights, meaning liquidity for these specific shares is limited in the short term.
- Warrant overhang: The issuance of warrants equal to 100% of the shares sold creates significant potential dilution upon exercise.
📋 Key Facts
- Total gross proceeds: Approximately $2.715 million.
- Issuance of 1,686,667 Investor Shares at $1.50 per share.
- Issuance of warrants to purchase up to 1,686,667 shares at an exercise price of $1.87 (the greater of book or market value).
- Warrants have a one-year delay before exercise and a six-year term.
- Directors Stan Smith and Ramiro Guerrero participated in the offering to align interests.
- Proceeds are earmarked for Part C of the Phase II THIO-101 trial and working capital.
MAIA Biotechnology, Inc. has amended the employment agreements for its CEO (Dr. Vlad Vitoc) and CSO (Dr. Sergei Gryaznov), resulting in significant base salary increases and adjusted bonus structures. The filing also notes a minor salary increase for Jeffrey Himmelreich.
🚩 Red Flags
- Increased executive compensation in a micro-cap environment can sometimes signal cash burn concerns, though not explicitly stated here.
📋 Key Facts
- CEO Dr. Vlad Vitoc's annual base salary increased from $473,000 to $625,000.
- Dr. Vitoc's discretionary cash bonus target increased from 50% to 55% of base salary.
- CSO Dr. Sergei Gryaznov's annual base salary increased from $363,000 to $489,000.
- Dr. Gryaznov's discretionary cash bonus target increased from 40% to 45% of base salary.
- Jeffrey Himmelreich's base salary increased from $250,000 to $275,000 effective February 1, 2025.
MAIA Biotechnology, Inc. issued an 8-K to announce efficacy updates from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer and provided a business presentation.
📋 Key Facts
- Announced efficacy updates for the Phase 2 THIO-101 trial in advanced non-small cell lung cancer on February 4, 2025.
- Released a company business presentation via its website on February 5, 2025.
- The clinical data was released pursuant to Regulation FD.
MAIA Biotechnology, Inc. has significantly increased the maximum aggregate offering price of its common stock under an existing At The Market (ATM) Sales Agreement with H.C. Wainwright & Co. from $11.28 million to $30 million.
🚩 Red Flags
- Potential for future dilution of existing shareholders through increased ATM capacity.
- The company has already utilized nearly 90% of its previous $11.28M offering limit, indicating a high reliance on equity financing to fund operations.
📋 Key Facts
- Increased ATM offering capacity from $11,280,000 to $30,000,000.
- The increase is pursuant to an existing Sales Agreement dated February 14, 2024.
- Prior to this filing, the company had already sold approximately $10,111,994 in shares under the original agreement.
- Legal opinion regarding the legality of the new share issuance was filed as Exhibit 5.1.
MAIA Biotechnology announced that the FDA has granted 'rare pediatric disease' designation to its drug candidate, THIO, for the treatment of pediatric-type diffuse high-grade gliomas (PDHGG). This regulatory milestone is a positive development for the company's clinical pipeline.
📋 Key Facts
- FDA designated THIO as a drug for 'rare pediatric disease'.
- Target indication: Pediatric-type diffuse high-grade gliomas (PDHGG).
- Announcement date of event: December 16, 2024.
MAIA Biotechnology entered into a Securities Purchase Agreement to conduct a private placement of common stock and warrants totaling approximately $950,000. The proceeds are intended for manufacturing THIO for Phase II clinical trials and general working capital.
🚩 Red Flags
- Related-party transaction: Director Ramiro Guerrero's sister, Sylvia Guerrero, participated in the private placement.
- Small offering size ($950k) suggests limited runway and potential ongoing need for frequent dilutive financing.
- Securities are being issued as restricted securities without immediate registration rights.
📋 Key Facts
- Total expected gross proceeds: ~$950,000.
- Issuance includes 428,946 investor shares and warrants to purchase up to 428,946 shares at $1.872 per share.
- Warrants are exercisable at $2.08 (the greater of book or market value) starting six months after issuance for a term of five years.
- Directors Stan Smith and Ramiro Guerrero participated in the offering via Unrestricted Stock Awards/Options under the 2021 Equity Incentive Plan.
- Closing is expected on December 11, 2024.
MAIA Biotechnology released new efficacy data from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer (NSCLC) to be presented at the SITC 39th Annual Meeting. The company also issued a business presentation and a summary highlighting its partnership with Regeneron.
🚩 Red Flags
- Clinical trial results are interim and subject to change or further validation.
- The company continues to operate under forward-looking statements regarding clinical progress and regulatory approvals.
📋 Key Facts
- Phase 2 THIO-101 clinical trial data evaluated in combination with cemiplimab (Libtayo®) for advanced NSCLC patients who failed 2+ standard-of-care regimens.
- As of September 16, 2024, 19 patients had survival follow-up exceeding 12 months.
- Interim median survival in the third-line (3L) setting across all dose levels was 11.5 months.
- Interim median survival in the 3L setting for the THIO 180mg dose was 11.4 months.
- The data was selected as a 'late-breaking abstract' for the Society for Immunotherapy of Cancer (SITC) meeting on November 8, 2024.
MAIA Biotechnology announced that a late-breaking abstract regarding THIO-101 updates has been selected for oral and poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This is a routine clinical/scientific update announcement.
📋 Key Facts
- Selected for oral and poster presentation at SITC 39th Annual Meeting.
- Subject matter: Late-breaking abstract updates for THIO-101.
- Filing date: November 5, 2024.
MAIA Biotechnology entered into a Securities Purchase Agreement on October 28, 2024, to conduct a private placement of common stock and warrants totaling approximately $4.4 million in gross proceeds. The offering includes participation from several company directors and is intended to fund THIO manufacturing for Phase II clinical trials and general working capital.
🚩 Red Flags
- Related-party transactions: Significant portion of the offering ($575,895 in shares/warrants) is being taken up by company directors and a director's son.
- Dilution risk: Issuance of nearly 1 million new shares plus warrants for an additional 1.08 million potential shares upon exercise.
📋 Key Facts
- Aggregate gross proceeds expected: ~$4.4 million (prior to expenses).
- Issuance of 846,984 Investor Shares and 846,984 Investor Warrants at $2.259 per share.
- Warrant exercise price: $2.51 (greater of book or market value).
- Director participation includes 232,800 Director Shares and 232,800 Director Warrants at $2.259 per share.
- Specific director subscriptions: Stan Smith ($225,900), Ramiro Guerrero ($200,000), Steven Chaouki ($50,000), Cristian Luput ($50,000).
- A family member of Director Stan Smith subscribed for 40,000 shares and warrants.
- Warrants have a five-year term and are exercisable after six months.
- Proceeds earmarked for THIO manufacturing (Phase II trials) and working capital.
MAIA Biotechnology issued an 8-K to provide a corporate presentation and summary for the H.C. Wainwright 26th Annual Global Investment Conference, alongside announcing positive survival updates from its Phase 2 study of THIO in Non-Small Cell Lung Cancer.
📋 Key Facts
- Company presented at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.
- Released a summary highlighting business operations, clinical programs, and a clinical supply agreement with Regeneron.
- Announced positive survival updates in its Phase 2 Study of THIO for Non-Small Cell Lung Cancer (NSCLC).
MAIA Biotechnology, Inc. issued a press release announcing positive treatment updates from its Phase 2 THIO-101 clinical trial on July 23, 2024.
📋 Key Facts
- Announced positive treatment updates regarding the Phase 2 THIO-101 clinical trial.
- The announcement was made via a press release dated July 23, 2024.
- Company is classified as an emerging growth company.
MAIA Biotechnology, Inc. issued a press release via Item 7.01 to announce year-to-date achievements and clinical progress regarding its novel anticancer agent. This is a regulatory disclosure of non-material information under Regulation FD.
📋 Key Facts
- Date of report: June 6, 2024
- The company issued a press release announcing YTD achievements and clinical progress for a novel anticancer agent.
- Information is furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
MAIA Biotechnology issued an 8-K to provide a business presentation, a summary of clinical programs and partnerships (specifically mentioning Regeneron), and new clinical data regarding THIO efficacy in Non-Small Cell Lung Cancer.
📋 Key Facts
- Company released a business presentation on June 4, 2024.
- Released a summary highlighting clinical programs and the partnership with Regeneron.
- Announced new clinical data showing THIO's efficacy in Non-Small Cell Lung Cancer (NSCLC).
- The filing includes forward-looking statements regarding clinical study progress and regulatory approvals.
MAIA Biotechnology released clinical efficacy data from its Phase 2 THIO-101 trial via a poster and supporting deck presented at the ASCO 2024 Annual Meeting. The data evaluates THIO sequenced with cemiplimab in patients with advanced non-small cell lung cancer (NSCLC).
🚩 Red Flags
- The company includes a disclaimer stating that investors should not place undue reliance on the forward-looking statements contained in the clinical data presentation.
📋 Key Facts
- Clinical trial: Phase 2 THIO-101.
- Therapy combination: THIO sequenced with immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®).
- Patient population: Advanced non-small cell lung cancer (NSCLC) patients who failed 2 or more standard-of-care regimens.
- Event: Data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on June 3, 2024.
MAIA Biotechnology, Inc. held its 2024 Annual Meeting of stockholders on May 24, 2024. The meeting resulted in the re-election of all Class II director nominees and the ratification of Grant Thornton LLP as the company's independent auditor for fiscal year 2024.
📋 Key Facts
- Annual Meeting held on May 24, 2024.
- Quorum was present with 14,610,088 shares representing approximately 70.98% of outstanding common stock.
- Vlad Vitoc, Ramiro Guerrero, and Cristian Luput were re-elected to the Board of Directors.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
MAIA Biotechnology, Inc. has increased the maximum aggregate offering price of its common stock under an existing At The Market (ATM) Sales Agreement with H.C. Wainwright & Co. from $4.95 million to $11.28 million.
🚩 Red Flags
- Potential dilution for existing shareholders due to increased ATM capacity.
- Continuous need for capital (implied by the expansion of the ATM facility).
📋 Key Facts
- Increased ATM offering capacity from $4,950,000 to $11,280,000.
- Prior sales under the agreement totaled approximately $3,010,412.
- The increase is being executed via a prospectus supplement filed under the existing Sales Agreement dated February 14, 2024.
- The offering involves common stock with a par value of $0.0001 per share.
MAIA Biotechnology, Inc. filed an 8-K to provide a business presentation via its website as part of Regulation FD disclosures. The filing contains no material changes to operations, finances, or management.
📋 Key Facts
- Company posted a business presentation to its website on May 7, 2024.
- The presentation is intended to provide summary information about the Company's business.
- The filing includes Exhibit 99.1 containing the presentation materials.
MAIA Biotechnology entered into a Securities Purchase Agreement for a private placement of common stock and warrants totaling approximately $1.0 million. The proceeds are specifically earmarked to fund R&D for the THIO-101 trial in non-small cell lung cancer (NSCLC).
🚩 Red Flags
- Small capital raise ($1.0M) suggests limited runway or high burn rate typical of clinical-stage biotech.
- Securities are being issued as restricted securities without immediate registration rights.
- Warrants include a 6-month exercise delay, which can lead to future dilution.
📋 Key Facts
- Total gross proceeds expected: ~$1.0 million.
- Issuance of 326,939 investor shares and 326,939 warrants at $2.034 per share/unit.
- Warrants exercisable at $2.26 (greater of book or market value) with a 5-year term.
- Directors Stan Smith and Louie Ngar Yee participated in the offering to align interests.
- Proceeds intended for THIO-101 trial Part C in NSCLC.
MAIA Biotechnology, Inc. filed an 8-K reporting a compensation adjustment for Jeffrey Himmelreich, effective April 1, 2024.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Effective date of change: April 1, 2024.
- Base salary increased to $250,000 under the employment agreement dated August 30, 2023.
- Target Annual Bonus increased to 25% of Base Salary.
MAIA Biotechnology entered into a Securities Purchase Agreement to conduct a private placement of common stock and warrants totaling approximately $1.33 million. The proceeds are earmarked for R&D, specifically the THIO-101 clinical trial.
🚩 Red Flags
- Issuance of warrants may lead to future dilution for existing shareholders.
- The securities are being issued as restricted securities without immediate registration rights.
📋 Key Facts
- Private placement of 578,643 shares of common stock and an equal number of warrants.
- Aggregate purchase price: approximately $1.33 million.
- Common stock issuance price: $2.295 per share.
- Warrants are exercisable at $2.55 per share (the greater of book or market value).
- Warrant exercise period begins 6 months after issuance with a 5-year term.
- Use of proceeds: Funding the first third of the pivotal accelerated approval Part C THIO-101 trial in NSCLC.
MAIA Biotechnology, Inc. has increased the maximum aggregate offering price under its existing At The Market (ATM) Offering Agreement with H.C. Wainwright & Co. from $1.445 million to $4.95 million.
🚩 Red Flags
- Continued use of ATM offerings suggests ongoing need for liquidity/cash runway extension.
- Potential dilution for existing shareholders as new shares are issued to raise capital.
📋 Key Facts
- Increased ATM offering capacity from $1,445,000 to $4,950,000.
- Prior sales under the agreement totaled $745,250.
- The increase is being executed via a Current Prospectus Supplement filed on March 25, 2024.
- Agreement partner: H.C. Wainwright & Co.
MAIA Biotechnology entered into a Securities Purchase Agreement on March 11, 2024, to conduct a private placement of common stock and warrants totaling approximately $2.92 million. The proceeds are intended to fund R&D activities, specifically for the THIO-101 trial in NSCLC.
🚩 Red Flags
- Related-party transaction: Board members participated directly in the private placement.
- Dilution risk: Issuance of over 2 million shares plus warrants representing significant potential dilution for existing shareholders.
- Restricted securities: The shares and warrants are being issued as restricted securities without immediate registration rights.
📋 Key Facts
- Total gross proceeds expected: ~$2.92 million (prior to expenses).
- Issuance of 2,043,587 investor shares and warrants to purchase up to 2,043,587 shares at $1.17/share.
- Warrants are exercisable at $1.30 per share (greater of book or market value) starting in six months for a term of five years.
- Directors participated in the offering, subscribing to 452,731 shares and warrants at $1.17/share ($529,695).
- Use of proceeds: Funding research and development, specifically the first third of the pivotal accelerated approval Part C of the THIO-101 trial in NSCLC.
- Expected closing date: March 14, 2024.
MAIA Biotechnology announced positive efficacy data from its Phase 2 THIO-101 clinical trial and scheduled upcoming presentations at major industry conferences.
📋 Key Facts
- Announced positive efficacy data in the Phase 2 THIO-101 clinical trial on March 6, 2024.
- Scheduled to present with Nationwide Children’s Hospital at the AACR Annual Meeting (April 5–10, 2024).
- Participating in the 36th Annual ROTH Conference (March 17-19, 2024).
MAIA Biotechnology, Inc. issued a 2024 Letter to Shareholders and a corresponding press release detailing its immuno-oncology cancer treatment candidates and development pipeline.
📋 Key Facts
- The company released its 2024 Letter to Shareholders on March 5, 2024.
- The filing focuses on the Company's immuno-oncology cancer treatment candidates and R&D pipeline.
- The report includes standard forward-looking statement cautionary language regarding clinical studies and regulatory approvals.
MAIA Biotechnology, Inc. announced the appointment of Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board via a press release issued on February 27, 2024.
📋 Key Facts
- Appointment of Remus Vezan, M.D., Ph.D. to the Scientific Advisory Board.
- Filing date: February 27, 2024.
MAIA Biotechnology, Inc. announced the completion of patient enrollment for its THIO-101 Phase 2 Clinical Trial targeting Non-Small Cell Lung Cancer (NSCLC) on February 22, 2024.
📋 Key Facts
- Completed enrollment for the THIO-101 Phase 2 Clinical Trial.
- The clinical trial targets Non-Small Cell Lung Cancer (NSCLC).
- Announcement date: February 22, 2024.
MAIA Biotechnology entered into an At The Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $1,445,000 of common stock.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
📋 Key Facts
- Entered into ATM Agreement on February 14, 2024.
- Aggregate sales price cap: $1,445,000.
- Sales agent: H.C. Wainwright & Co., LLC.
- Commission rate: 3.0% of aggregate gross proceeds.
- Shares to be issued under existing Form S-3 shelf registration (effective August 23, 2023).
MAIA Biotechnology announced that the World Intellectual Property Organization published its international patent application for dinucleotide compounds used in cancer treatment. The company expects this to enhance the value of its telomere-targeting therapeutic platform.
📋 Key Facts
- Patent title: 'Dinucleotides and Their Use in Treating Cancer'.
- Technology targets telomeres in cancer cells using dinucleotide compounds (e.g., THIO fragments).
- Potential application includes use alone or in combination with checkpoint inhibitors.
- The patent publication was announced on January 24, 2024.
MAIA Biotechnology announced positive interim clinical data for its THIO-101 Phase 2 trial in non-small cell lung cancer patients. The results showed high disease control rates (DCR) and met statistical requirements to proceed to the next stage of the trial earlier than expected.
📋 Key Facts
- Interim data from THIO-101 as of November 13, 2023, included 60 patients dosed in combination with Libtayo®.
- Observed 100% preliminary disease control rate (DCR) in second-line patients and 88% in third-line patients.
- Trial met pre-determined statistical requirements earlier than expected to proceed to the next stage.
- Company announced key 2024 milestone: development of a second-generation telomere-targeting program using lipid-modified THIO molecules for higher potency.